EUVIMEDEUVIMED entdecken
Crossref

The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program

Amelia M Bond, Emma B Dean, Sunita M Desai

Health Affairs · 01.05.2023 · 42 (5) · 632-641

DOI: 10.1377/hlthaff.2022.00812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs, erschienen am 01.05.2023. Verfasst von Amelia M Bond und 2 weiteren Autor:innen. Beteiligte Einrichtung: Amelia M. Bond (amb2036@med.cornell.edu), Cornell University, New York, New York. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Medicare, Reimbursement, Incentive. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: AHRQ HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biosimilar drugs-lower-cost alternatives to expensive biologic drugs-have the potential to slow the growth of US drug spending. However, rates of biosimilar uptake have varied across hospital outpatient providers. We investigated whether the 340B Drug Pricing Program, which offers eligible hospitals substantial discounts on drug purchases, inhibits biosimilar uptake. Almost one-third of US hospitals participate in the 340B program. Using a regression discontinuity design and two high-volume biologics with biosimilar competitors, filgrastim and infliximab, we estimated that 340B program eligibility was associated with a 22.9-percentage-point reduction in biosimilar adoption. In addition, 340B program eligibility was associated with 13.3 more biologic administrations annually per hospital and $17,919 more biologic revenue per hospital. Our findings suggest that the program inhibited biosimilar uptake, possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsMedicareReimbursement, IncentiveAgedHumansDrug CostsHospitalsProgram EvaluationUnited States

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Amelia M. Bond (amb2036@med.cornell.edu), Cornell University, New York, New York.
  • Emma B. Dean, University of Miami, Miami, Florida.
  • Sunita M. Desai, New York University, New York, New York.

Förderung

  • AHRQ HHS

Zitieren

APA

Bond, A. M., Dean, E. B., & Desai, S. M. (2023). The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program. Health Affairs, 42(5), 632-641. https://doi.org/10.1377/hlthaff.2022.00812

Vancouver

Bond AM, Dean EB, Desai SM. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program. Health Affairs. 2023;42(5):632-641. doi:10.1377/hlthaff.2022.00812

BibTeX
@article{Bond2023,
  author = {Bond, Amelia M and Dean, Emma B and Desai, Sunita M},
  title = {The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program},
  journal = {Health Affairs},
  year = {2023},
  volume = {42},
  number = {5},
  pages = {632--641},
  doi = {10.1377/hlthaff.2022.00812}
}
Kostenlos starten →